Skip to main content

Advertisement

SpringerLink
Log in

Update on Progressive Multifocal Leukoencephalopathy

  • Infection (B Jubelt, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe, often fatal, opportunistic viral infection of the central nervous system that is mainly seen in the context of AIDS and certain monoclonal immune-suppressive therapies. The causative agent, a polyoma virus, named JC virus infects only humans and there is no animal model for PML. This update focuses on information gathered in recent years on the pathogenesis of the disorder, on several clinical aspects associated with diagnosis and therapy, and on the immune reconstitution inflammatory syndrome (IRIS), a complication associated with removal of immunosuppressive therapy in PML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Astrom KE, Mancall EL, Richardson Jr EP. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain. 1958;81:93–111.

    Article  PubMed  CAS  Google Scholar 

  2. Padgett BL, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1:1257–60.

    Article  PubMed  CAS  Google Scholar 

  3. Weiner LP, et al. Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med. 1972;286:385–90.

    Article  PubMed  CAS  Google Scholar 

  4. Stoner G, Ryschkewitsch C. Evidence of JC virus in two progressive multifocal leukoencephalopathy (PML) brains previously reported to be infected with SC40. J Neuropathol Exp Neurol. 1991;50:342.

    Google Scholar 

  5. • Gorelik L, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295–303. A study from a leading group in the field that deals with reducing the risk of PML in patients about to receive immuno-suppressive therapies.

    Article  PubMed  Google Scholar 

  6. Stolt A, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol. 2003;84:1499–504.

    Article  PubMed  CAS  Google Scholar 

  7. Walker D, Padgett B. The epidemiology of human polyomaviruses. In: Sever J, Madden D, editors. Polyomaviruses and human neurological disease. New York: Alan R. Liss, Inc; 1983. p. 99–106.

    Google Scholar 

  8. Bofill-Mas S, Girones R. Excretion and transmission of JCV in human populations. J Neuroviro. 2001;7:345–9.

    Article  CAS  Google Scholar 

  9. Zaheer F, Berger JR. Treatment related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Advances Drug Safety. 2012 (in press).

  10. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2:299–313.

    PubMed  CAS  Google Scholar 

  11. Berger JR, et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107:78–87.

    PubMed  CAS  Google Scholar 

  12. Kure K, et al. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol. 1991;22:700–10.

    Article  PubMed  CAS  Google Scholar 

  13. Collazos J. Opportunistic infections of the CNS in patients with AIDS: diagnosis and management. CNS Drugs. 2003;17:869–87.

    Article  PubMed  Google Scholar 

  14. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.

    Article  PubMed  CAS  Google Scholar 

  15. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab–unforeseen consequences. N Engl J Med. 2005;353:414–6.

    Article  PubMed  CAS  Google Scholar 

  16. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–74.

    Article  PubMed  CAS  Google Scholar 

  17. Langer-Gould A, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–81.

    Article  PubMed  CAS  Google Scholar 

  18. Van Assche G, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362–8.

    Article  PubMed  Google Scholar 

  19. BiogenIdec. PML incidence in patients receiving TYSABRI. 2012 [cited July 2, 2012]; Available at: https://medinfo.biogenidec.com/medinfo/secure/pmlresource.do?resource=TYSABRIPMLSafetyUpdate. Accessed 10 July 2012.

  20. • Bloomgren G, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Eng J Med. 2012;366:1870–80. A recent study that assesses who is at risk to develop PML under natalizumab therapy.

    Article  CAS  Google Scholar 

  21. Gordon KB, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073–80.

    Article  PubMed  CAS  Google Scholar 

  22. Lebwohl M, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–13.

    Article  PubMed  CAS  Google Scholar 

  23. Carson KR, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on adverse drug events and reports project. Blood. 2009;113:4834–40.

    Article  PubMed  CAS  Google Scholar 

  24. Garcia-Suarez J, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80:271–81.

    Article  PubMed  CAS  Google Scholar 

  25. Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neuroviro. 2003;9 Suppl 1:38–41.

    CAS  Google Scholar 

  26. Caldarelli-Stefano R, et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neuroviro. 1999;5:125–33.

    Article  CAS  Google Scholar 

  27. Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neuroviro. 2001;7:280–7.

    Article  CAS  Google Scholar 

  28. Major EO, et al. Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. J Neurosci Res. 1990;27:461–71.

    Article  PubMed  CAS  Google Scholar 

  29. Monaco MC, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996;70:7004–12.

    PubMed  CAS  Google Scholar 

  30. Houff SA, Berger JR. The bone marrow, B cells, and JC virus. J Neuroviro. 2008;14:341–3.

    Article  Google Scholar 

  31. Sunyaev SR, et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009;5:e1000368.

    Article  PubMed  Google Scholar 

  32. Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? Curr Opin Neurol. 2011;24:268–74.

    Article  PubMed  Google Scholar 

  33. Weber F, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol. 2001;49:636–42.

    Article  PubMed  CAS  Google Scholar 

  34. Berger JR, et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS. 1992;6:837–41.

    Article  PubMed  CAS  Google Scholar 

  35. Fedele CG, et al. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neuroviro. 2003;9:551–8.

    CAS  Google Scholar 

  36. Katz DA, et al. Progressive multifocal leukoencephalopathy complicating Wiskott-Aldrich syndrome. Report of a case and review of the literature of progressive multifocal leukoencephalopathy with other inherited immunodeficiency states. Arch Neurol. 1994;51:422–6.

    Article  PubMed  CAS  Google Scholar 

  37. Andreoletti L, et al. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy. J Med Virol. 2002;66:1–7.

    Article  PubMed  CAS  Google Scholar 

  38. Tornatore C, et al. Detection of JC viral genome in the lymphocytes of non-PML HIV positive patients: association with B cell lymphopenia. Neurology. 1992;42 Suppl 3:211.

    Google Scholar 

  39. Berenguer J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003;36:1047–52.

    Article  PubMed  CAS  Google Scholar 

  40. Cinque P, et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neuroviro. 2001;7:358–63.

    Article  CAS  Google Scholar 

  41. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol. 2001;75:3483–7.

    Article  PubMed  CAS  Google Scholar 

  42. Krumbholz M, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71:1350–4.

    Article  PubMed  CAS  Google Scholar 

  43. Du Pasquier RA, et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neuroviro. 2001;7:318–22.

    Article  Google Scholar 

  44. Du Pasquier RA, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain. 2004;127:1970–8.

    Article  PubMed  Google Scholar 

  45. Marzocchetti A, et al. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. Virology. 2009;383:173–7.

    Article  PubMed  CAS  Google Scholar 

  46. del Pilar Martin M, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008;65:1596–603.

    Article  PubMed  Google Scholar 

  47. Jullien D, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology. 2004;208:297–306.

    Article  PubMed  CAS  Google Scholar 

  48. Papp KA. Efalizumab: advancing psoriasis management with a novel, targeted T-cell modulator. Drugs Today (Barc). 2004;40:889–99.

    Article  CAS  Google Scholar 

  49. Capsoni F, et al. Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. Int J Immunopathol Pharmacol. 2008;21:437–45.

    PubMed  CAS  Google Scholar 

  50. Lowes MA, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A. 2005;102:19057–62.

    Article  PubMed  CAS  Google Scholar 

  51. • Schwab N, et al. Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control. Neurology. 2012;78:458–67. discussion 465. A recent observation on the possible pathogenesis of PML under monoclonal antibody therapy.

    Article  PubMed  CAS  Google Scholar 

  52. Cross AH, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63–70.

    Article  PubMed  CAS  Google Scholar 

  53. Marshall LJ, Major EO. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J Neuroimmune Pharmacol. 2010;5:404–17.

    Article  PubMed  Google Scholar 

  54. Tornatore C, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol. 1992;31:454–62.

    Article  PubMed  CAS  Google Scholar 

  55. Berger JR, et al. Are saliva and oropharyngeal secretions a source of JCV infection? J Neuroviro. 2005;11 Suppl 2:83.

    Google Scholar 

  56. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy–revisited. J Infect Dis. 2011;203:578–86.

    Article  PubMed  Google Scholar 

  57. Bayliss J, et al. Immunosuppression increases latent infection of brain by JC polyomavirus. Pathology. 2011;43:362–7.

    Article  PubMed  Google Scholar 

  58. Rushing EJ, et al. Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. J Neuropathol Exp Neurol. 2008;67:819–27.

    Article  PubMed  Google Scholar 

  59. Manabe YC, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46:456–62.

    Article  PubMed  CAS  Google Scholar 

  60. Shelburne SA, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19:399–406.

    Article  PubMed  Google Scholar 

  61. Price P, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS. 2002;16:2043–7.

    Article  PubMed  CAS  Google Scholar 

  62. Falco V, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr. 2008;49:26–31.

    Article  PubMed  Google Scholar 

  63. Clifford DB, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–46.

    Article  PubMed  CAS  Google Scholar 

  64. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2010;68:186–91.

    Article  PubMed  Google Scholar 

  65. • Johnson T, Nath A. Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol. 2011;24:284–90. A recent comprahensive review on IRIS.

    Article  PubMed  CAS  Google Scholar 

  66. Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther. 2011;9:415–30.

    Article  PubMed  CAS  Google Scholar 

  67. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425–37.

    Article  PubMed  CAS  Google Scholar 

  68. Meintjes G, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24:2381–90.

    PubMed  CAS  Google Scholar 

  69. Hartung HP. et al [Therapie der Multiplen Sklerose mit monokonalen Antikorpen: aktualisierte Empfelungen im Rahmen eines Expert meetings]. Actuelle Neurol. 2011;38:2–11.

    Article  Google Scholar 

  70. Berger JR. Steroids for PML-IRIS: a double-edged sword? Neurology. 2009;72:1454–5.

    Article  PubMed  Google Scholar 

  71. Berger JR. The clinical features of PML. Cleve Clin J Med. 2011;78 Suppl 2:S8–12.

    Article  PubMed  Google Scholar 

  72. Whiteman ML, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology. 1993;187:233–40.

    PubMed  CAS  Google Scholar 

  73. Berger JR, et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neuroviro. 1998;4:59–68.

    Article  CAS  Google Scholar 

  74. De Luca A, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 2008;22:1759–67.

    Article  PubMed  Google Scholar 

  75. Marra CM, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16:1791–7.

    Article  PubMed  CAS  Google Scholar 

  76. De Luca A, et al. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis. 1999;28:624–8.

    Article  PubMed  Google Scholar 

  77. Hall CD, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team [see comments]. N Engl J Med. 1998;338:1345–51.

    Article  PubMed  CAS  Google Scholar 

  78. Elphick GF, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306:1380–3.

    Article  PubMed  CAS  Google Scholar 

  79. Marzocchetti A, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 2009;73:1551–8.

    Article  PubMed  CAS  Google Scholar 

  80. Brickelmaier M, et al. Identification and characterization of mefloquine efficacy against Jc virus in vitro. Antimicrob Agents Chemother. 2009.

  81. Beppu M, et al. Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. Intern Med. 2012;51(10):1245–7.

    PubMed  CAS  Google Scholar 

  82. Moenster RP, Jett RA. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm. 2012;69(6):496–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

I. Steiner: none; J. R. Berger: consultant (Amgen, Bayer, Millenium, Genentech, and Novartis) and speakers’ bureaus (Novartis, Bayer, and Biogen Idec).

Author information

Authors and Affiliations

  1. Department of Neurology, Rabin Medical Center-Beilinson Campus, 49100, Petach Tikva, Israel

    Israel Steiner

  2. Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, USA

    Joseph R. Berger

Authors
  1. Israel Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph R. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Israel Steiner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steiner, I., Berger, J.R. Update on Progressive Multifocal Leukoencephalopathy. Curr Neurol Neurosci Rep 12, 680–686 (2012). https://doi.org/10.1007/s11910-012-0313-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-012-0313-4

Keywords

Search

Navigation